Article (Scientific journals)
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
Scheen, André
2021In Diabetes and Metabolism
Peer reviewed
 

Files


Full Text
1-s2.0-S1262363620301786-main.pdf
Publisher postprint (3.54 MB)
pre-proofs
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Gliptin; Incretin; Inflammation; Mortality; Outcome; SARS-CoV-2
Abstract :
[en] Dipeptidyl peptidase-4 inhibitors (DPP-4is) have gained a key place in the management of type 2 diabetes mellitus (T2DM) essentially because of their good safety profile even in the frail population. DPP-4, originally known as 'T-cell antigen CD26', is expressed in many immune cells and regulates their functions, so the initial concern over the use of DPP-4is was the possible increased susceptibility to infections. Furthermore, because of the high affinity between human DPP-4 and the spike (S) receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it was suspected that this virus, responsible for coronavirus disease 2019 (COVID-19), might be able to use the DPP-4 enzyme as a functional receptor to gain entry into the host. However, DPP-4is also exert anti-inflammatory effects, which could be beneficial in patients exposed to cytokine storms due to COVID-19. Yet, when observational (mostly retrospective) studies compared clinical outcomes in DPP-4i users vs non-users among diabetes patients with COVID-19, the overall results regarding the risk of progression towards more severe forms of the disease and mortality were heterogeneous, thereby precluding any definite conclusions. Nevertheless, new expectations have arisen following recent reports of significant reductions in admissions to intensive care units and mortality in DPP-4i users. However, given the limitations inherent in such observational studies, any available results should be considered, at best, as hypothetical and only suggestive of potentially substantial benefits with DPP-4is in diabetes patients with COVID-19. While the safe use of DPP-4is in COVID-19 patients appears to be an acceptable hypothesis, all such positive findings still need to be confirmed in randomized controlled trials (a few of which are currently ongoing) before any recommendations can be made for clinical practice.
Disciplines :
Immunology & infectious disease
Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Language :
English
Title :
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
Publication date :
2021
Journal title :
Diabetes and Metabolism
ISSN :
1262-3636
eISSN :
1878-1780
Peer reviewed :
Peer reviewed
Commentary :
Copyright © 2020. Published by Elsevier Masson SAS.
Available on ORBi :
since 03 December 2020

Statistics


Number of views
48 (1 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
34
Scopus citations®
without self-citations
31
OpenCitations
 
22

Bibliography


Similar publications



Contact ORBi